ESMO
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
Exact Sciences Blood-Based Colon Cancer Screening Data at ESMO Exceeds Expectations
Although the results were better than expected, the company cautioned that it expects lower performance in its prospective trial readout, planned for early next year.